-
Blue Origin set to launch rocket with reusable booster for first time
-
Strait of Hormuz to stay closed until port blockade lifts, Iran says
-
Iraq fish die-off leaves farmers mourning lost livelihoods
-
Crisis-hit Bulgaria votes in eighth election in five years
-
'Pure joy' for Matarazzo after Copa del Rey triumph
-
Messi scores winner as Miami down Colorado on coach debut
-
Nuggets hold off T'Wolves, Cavs thump Raptors in NBA playoff openers
-
Fitzpatrick extends lead as Scheffler charges at RBC Heritage
-
Real Sociedad secure Copa del Rey penalty triumph over Atletico
-
'Scandalous' Marseille lose at Lorient, dent Champions League bid
-
Arteta urges Arsenal to have no regrets in Man City title showdown
-
Substitute Dupont helps Toulouse cruise past Castres in Top 14
-
Questions surround Warriors after NBA play-in exit
-
Man Utd beat Chelsea as Spurs stunned by Brighton equaliser
-
Cunha steers Man Utd towards Champions League at Chelsea's expense
-
Cavs cruise past Raptors in NBA playoff opener
-
England beat Iceland to stay perfect in Women's World Cup qualifying
-
Spurs 'not finished yet', says defiant De Zerbi
-
Germany's Gnabry a World Cup doubt after thigh injury
-
Spurs stunned by late Brighton equaliser, Leeds pull clear of trouble
-
At least 6 killed after gunman opens fire in Ukrainian capital
-
Relegation-haunted Spurs count cost of Brighton draw
-
Spurs count cost after Brighton draw leaves them in drop zone
-
'Scandalous' Marseille lose at Lorient, damage Champions League bid
-
Abhishek fireworks, Malinga spell sink Chennai
-
Napoli's Serie A title defence nears end with Lazio defeat
-
England run in 12 tries to hammer Scotland in Six Nations
-
Rybakina powers past Andreeva to reach Stuttgart final
-
At least 5 killed after gunman opens fire in Ukrainian capital
-
Rublev, Fils fightbacks set up Barcelona Open final
-
Leeds pull clear of trouble, Bournemouth sink Newcastle
-
Spain rout Ukraine to boost Women's World Cup qualifying hopes
-
Bayern close in on Bundesliga title as Dortmund lose
-
US extends sanctions waiver on purchases of Russian oil
-
Trump signs order to fast-track research on psychedelic drugs
-
Cobolli downs Zverev to set up Munich final with Shelton
-
Pope arrives in Angola on Africa tour overshadowed by Trump
-
Thousands protest in Germany urging faster green shift
-
La Rochelle thump threadbare Bordeaux-Begles
-
Trade ships hit in Hormuz as Iran recloses strait
-
Muchova battles past Svitolina to book Stuttgart final berth
-
Allegri rules out taking Italy job, wants to stay at AC Milan
-
Miller bludgeons Delhi to IPL win over Bengaluru
-
Pope says he regrets his remarks interpreted as a debate with Trump
-
Brentford blow chance for top six in Fulham stalemate
-
Trade ships hit in Hormuz as Iran reopening falters
-
France blames Hezbollah for French peacekeeper's death in Lebanon
-
Venezuela's Machado doesn't regret gifting Nobel Peace Prize to Trump
-
No date set for next round of Iran-US talks: Iran deputy FM
-
'We've already beaten other favorites', Lyon's Endrick warns PSG
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
I.Stoeckli--VB